Penn Medicine Provider
Medical Oncology
Ronac Mamtani, MD, MSCE
5.0
(156)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
Make an appointmentCall 215-615-5858

About me

  • Section Chief, Genitourinary Cancers, Hematology-Oncology
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: State University of New York at Stony Brook
  • Residency: NewYork-Presbyterian/Weill Cornell Medical Center
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
5.0

156 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

July 2025
5.0
5.0
professional
June 2025
5.0
5.0
very personable
June 2025
5.0
5.0
easy to talk to
June 2025
5.0
5.0
the care is beyond exceptional.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Mamtani is a Penn Medicine physician.

Qualifications and experience

My research

Lian Y, Voruganti T, Lu J, Long Q, Mamtani R. Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates , JAMA Netw Open, 8: 2025,e2519524

Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R. Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer , J Natl Cancer Inst, 117: 2025,1276-1278

Swami N, Hwang WT, Mamtani R, O'Hara MH, Chapin WJ. Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer , JAMA Netw Open, 8: 2025,e2515087

Kurian M, Nimgaonkar V, Elghawy O, Mamtani R. Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC) , American Society of Clinical Oncology Annual Meeting I 2025, Chicago, IL., 43(16): 2025

Kurian M, Ferrell WJ, Ulloa Perez E, Hubbard R, Joffe S, Mamtani R, Parikh RB, Lynch HF. Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011-2023: a cross-sectional analysis , BMJ Oncol, 4: 2025,e000659

Wang X, Long JB, Rothen J, Huang S, Soulos P, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Ma SM, Wang SY, Dinan MA, Gross CP. Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. , American Society of Clinical Oncology Annual Meeting I 2025, Chicago IL., 43(16): 2025

Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA. Adoption of Broad Genomic Profiling in Patients With Cancer , JAMA Oncol: 2025

Wang X, Long JB, Rothen J, Soulos PR, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Wang SY, Kunst N, Ma S, Huang S, Gross CP, Dinan MA. BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era , J Natl Compr Canc Netw, 23: 2025

Geynisman DM, Chepynoga K, Yates G, Tate A, Kurt M, Patel MY, Teitsson S, Mitra S, Mamtani R. Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial , Clin Genitourin Cancer: 2025

Barsouk A, Elghawy O, Sussman JH, Xu J, Mamtani R, Mei L. Survival disparities by sex with contemporary advanced urothelial carcinoma (aUC) therapy: A real-world analysis. , American Society of Clinical Oncology Genitourinary Cancers Symposium 2025, San Fran, CA., 43(5): 2025